Acute neurological manifestations associated with the SARS-CoV-2 virus

  • Funded by Fundação de Amparo à Pesquisa do Estado de São Paulo [São Paulo Research Foundation] (FAPESP)
  • Total publications:2 publications

Grant number: 2020/05984-2

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2020
  • Known Financial Commitments (USD)

    $31,790.8
  • Funder

    Fundação de Amparo à Pesquisa do Estado de São Paulo [São Paulo Research Foundation] (FAPESP)
  • Principle Investigator

    Pending
  • Research Location

    Brazil, Americas
  • Lead Research Institution

    Universidade de São Paulo
  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Disease pathogenesis

  • Special Interest Tags

    Gender

  • Study Subject

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

In 2019, an outbreak of respiratory disease associated with a new coronavirus, SARS-CoV-2, began in the city of Wuhan, China. Since then, this highly transmissible virus has motivated extreme isolation measures around the world, in an attempt to mitigate the infection of entire populations, concomitantly saturating medical services and collapsing health systems. Several coronaviruses are associated with neurological syndromes such as encephalitis, myelitis and Guillain-Barré syndrome, among them SARS-CoV-1, phylogenetically the human coronavirus closest to SARS-CoV-2. Thus, it is expected that similar manifestations affect patients in the current epidemic. OBJECTIVES: To characterize the epidemiological, clinical, laboratory, electrophysiological and radiological profile of patients affected by myelitis, encephalitis and / or acute peripheral polyneuropathy in the presence of an epidemic associated with the SARS-Cov-2 virus. METHODS: This is a prospective observational study, which will evaluate the epidemiological, clinical, laboratory, electrophysiological and radiological characteristics of patients diagnosed with encephalitis, myelitis and / or acute peripheral polyneuropathy during the SARS-Cov-2 epidemic period, assisted in co-participant institutions. Patients who are considered suspected cases of SARS-CoV-2 will be selected according to criteria defined by the Ministry of Health (MS) and the World Health Organization (WHO) in the presence of proven community transmission, who present concomitant or subsequent clinical suspicion (up to 60 days after an event associated with SARS-CoV-2) of viral encephalitis, viral myelitis and / or acute peripheral polyneuropathy.

Publicationslinked via Europe PMC

Last Updated:37 minutes ago

View all publications at Europe PMC

SARS-CoV-2/COVID-19: Clinical Course Among Subjects HIV-1-Infected in Sao Paulo.

Subacute Cognitive Impairment in Individuals With Mild and Moderate COVID-19: A Case Series.